SEC-sourced researchBeta

OCUL

OCULAR THERAPEUTIX, INC

US markets

Data passport

CIK: 0001393434
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 6, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 12:02 PM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

OCUL · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	58,443,000.0000	Feb 5, 2026
December 2024	63,723,000.0000	Feb 5, 2026
December 2025	51,951,000.0000	Feb 5, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	51,951,000.0000	-265,939,000.0000	-204,883,000.0000	808,057,000.0000	153,747,000.0000	Feb 5, 2026
December 2024	63,723,000.0000	-193,506,000.0000	-134,677,000.0000	457,935,000.0000	142,591,000.0000	Feb 5, 2026
December 2023	58,443,000.0000	-80,736,000.0000	-70,234,000.0000	—	—	Feb 5, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$51.95M	December 2025	Feb 5, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$63.72M	December 2024	Feb 5, 2026	10-K
Net incomeNetIncomeLoss	-$265.94M	December 2025	Feb 5, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$204.88M	December 2025	Feb 5, 2026	10-K
Total assetsAssets	$808.06M	December 2025	Feb 5, 2026	10-K
Total liabilitiesLiabilities	$153.75M	December 2025	Feb 5, 2026	10-K

New filings

Explore methodology ↗